Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|6|1|20-27

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.6, Iss.1, 2013-03, pp. : 20-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

By Burton Jack D   Goldenberg David M  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

By Jamal-Hanjani Mariam   Pettengell Ruth  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1441-1448

Informa Healthcare

Access to resources Recommend Favorite

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

By Mukherji Deborah   Pettengell Ruth  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1915-1923

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma

By Fanale Michelle A.   Younes Anas  

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 333-350

Adis International

Access to resources Recommend Favorite

Non-Hodgkin's Lymphoma in the Elderly: A Guide to Drug Treatment

By Niitsu N.  

Drugs & Aging, Vol. 14, Iss. 6, 1999-06 ,pp. : 447-457

Adis International

Access to resources Recommend Favorite